123 related articles for article (PubMed ID: 37615821)
1. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
Ramirez F; Alvarado L; Dwivedi A; Chacon J
J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
[TBL] [Abstract][Full Text] [Related]
2. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
3. Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007-2017 database.
Ramirez F; Riva H; Digbeu B; Samaniego M; Fernandez L; Mansour S; Vasquez R; Lopez DS; Chacon J
Cancer Causes Control; 2024 Feb; 35(2):265-275. PubMed ID: 37702966
[TBL] [Abstract][Full Text] [Related]
4. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
5. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
6. Disparities in Late-Stage Breast and Colorectal Cancer Diagnosis Among Hispanic, Non-Hispanic White, and Non-Hispanic Black Patients: a Retrospective Cohort Study of Texas Medicare Beneficiaries.
Nicot-Cartsonis MS; Digbeu BDE; Raji MA; Kuo YF
J Racial Ethn Health Disparities; 2023 Dec; 10(6):3168-3177. PubMed ID: 36575329
[TBL] [Abstract][Full Text] [Related]
7. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Association Between Social Determinants of Health and Receipt of Immunotherapy for Melanoma.
Ramirez F; Vasquez R; Gill J; Riva H; Zambrano A; Samaniego M; Fernandez L; Chacon J
J Drugs Dermatol; 2024 May; 23(5):311-315. PubMed ID: 38709695
[TBL] [Abstract][Full Text] [Related]
9. Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States.
Hao S; Snyder RA; Irish W; Parikh AA
PLoS Med; 2021 Oct; 18(10):e1003842. PubMed ID: 34695123
[TBL] [Abstract][Full Text] [Related]
10. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
11. Racial differences in time to treatment for melanoma.
Tripathi R; Archibald LK; Mazmudar RS; Conic RRZ; Rothermel LD; Scott JF; Bordeaux JS
J Am Acad Dermatol; 2020 Sep; 83(3):854-859. PubMed ID: 32277971
[TBL] [Abstract][Full Text] [Related]
12. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
13. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
[TBL] [Abstract][Full Text] [Related]
14. Health Disparities Influence Childhood Melanoma Stage at Diagnosis and Outcome.
Hamilton EC; Nguyen HT; Chang YC; Eberth JM; Cormier J; Elting LS; Austin MT
J Pediatr; 2016 Aug; 175():182-7. PubMed ID: 27233520
[TBL] [Abstract][Full Text] [Related]
15. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
16. Treatment and Survival Disparities of Colon Cancer in the Texas-Mexico Border Population: Cancer Disparities in Border Population.
Yan J; Hester CA; Zhu H; Yan J; Augustine MM; Porembka MR; Wang SC; Mansour JC; Iii HJZ; Yopp AC; Polanco PM
J Surg Res; 2021 Nov; 267():432-442. PubMed ID: 34237628
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.
Ma TM; Agarwal N; Mahal B; Barragan-Carrillo R; Spratt D; Rettig MB; Valle LF; Steinberg ML; Garraway I; Vapiwala N; Xiang M; Kishan AU
JAMA Netw Open; 2023 Dec; 6(12):e2345906. PubMed ID: 38039002
[TBL] [Abstract][Full Text] [Related]
18. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
19. Asian American and Pacific Islander patients with melanoma have increased odds of treatment delays: A cross-sectional study.
Fane LS; Wei AH; Tripathi R; Bordeaux JS
J Am Acad Dermatol; 2023 Sep; 89(3):529-536. PubMed ID: 37224968
[TBL] [Abstract][Full Text] [Related]
20. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
